Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Biomarkers in Personalized Therapy of Lung Cancer.

Advances in experimental medicine and biology - 1 Jan 2016

Cagle Philip T, Raparia Kirtee, Portier Bryce P

Abstract excerpt

The two clinically validated and Food and Drug Administration approved lung cancer predictive biomarkers (epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) translocations) occur in only about 20 % of lung adenocarcinomas and acquired resistance develops to first generation drugs. Several other oncogenic drivers for lung adenocarcinoma have emerged as potentially druggable targets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anaplastic Lymphoma Kinase
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-ret

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 26703797
DOI: 10.1007/978-3-319-24932-2_2

Genes

BRAF
ROS1
ALK
MET
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Biomarkers in Personalized Therapy of Lung Cancer.PMID 26703797Read ↗

Biomarkers in lung adenocarcinoma: a decade of progress.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

Molecular Testing of Lung CancersSemantic proximity Read ↗

Molecular Targets Beyond the Big 3.Semantic proximity Read ↗

Molecular testing and personalized treatment of lung cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Genetics and biomarkers in personalisation of lung cancer treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.